June 10, 2020

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Steven Ralston, CFA
312-265-9426
sralston@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

Arcadia Biosciences, Inc. (RKDA-NASDAQ)

Management confirms hemp seed order backlog of over $3 million and reiterates guidance of $10+ million in total revenues in 2020. Acquisition of Industrial Seed Innovations is expected to close in 3Q of 2020

A discounted cash flow (DCF) model that applies a 12.5% discount rate and a terminal price-to-sales ratio (P/S) of only 0.33 (which is the average P/S ratio of a large agricultural products company) indicates a NAV share price target of $12.00.

Current Price (06/09/20)	$4.01
Valuation	**$12.00**

OUTLOOK

Arcadia Biosciences (NASDAQ: RKDA) is an **innovative agricultural biotechnology company** with a broad and growing agricultural product portfolio focused predominately on improving crop traits and nutritional value. Management's current focus is on **hemp, wheat and soybeans** under the trademarked names of GoodHemp, GoodWheat and Verdeca HB4. **GoodHemp is anticipated to generate record revenues for the company in 2020**, while **GoodWheat** is being rolled out in the North American market. Moreover, the **HB4** soybean franchise is teed up to offer a blue sky opportunity if/when China grants an import license.

SUMMARY DATA

52-Week High	**$10.20**
52-Week Low	**$1.82**
One-Year Return (%)	**-20.98**
Beta	**-0.83**
Average Daily Volume (shrs.)	**196,441**
Shares Outstanding (million)	**10.05**
Market Capitalization ($ mil.)	**$40.29**
Short Interest Ratio (days)	**3.06**
Institutional Ownership (%)	**13.04**
Insider Ownership (%)	**19.04**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/M**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/M**
P/E using 2019 Estimate	**N/M**
P/E using 2020 Estimate	**N/M**

Risk Level	**Above Average**
Type of Stock	**Small-Growth**
Industry	**Agricultural Products**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2017	1.0 A	1.0 A	0.6 A	1.4 A	4.0 A
2018	0.2 A	0.4 A	0.4 A	0.5 A	1.5 A
2019	0.2 A	0.2 A	0.4 A	0.4 A	1.2 A
2020	0.3 A	1.5 E	3.2 E	4.8 E	9.8 E

Earnings per Share
(EPS is operating earnings before non-recurring items)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2017	-$1.90 A	-$1.88 A	-$2.12 A	-$1.39 A	-$7.28 A
2018	-$4.86 A	-$2.02 A	-$0.46 A	-$0.14 A	-$6.12 A
2019	-$0.86 A	-$1.04 A	-$0.92 A	-$0.44 A	-$3.07 A
2020	-$0.65 A	-$0.70 E	-$0.57 E	-$0.46 E	-$2.33 E

Quarterly revenues & EPS estimates may not equal annual numbers due to rounding. Operating EPS do not include change in fair value of common stock warrant liabilities.

© Copyright 2020, Zacks Investment Research. All Rights Reserved.

EXECUTIVE SUMMARY

Arcadia Biosciences (NASDAQ: RKDA) is **on the cusp of significant revenue growth, primarily from management's initiative into the hemp space**. Since launching the effort in February 2019, Arcadia is expected to generate revenues in excess of $8 million from the hemp business alone. Almost additional $2 million is anticipated to be generated by the company's promising GoodWheat franchise and legacy SONOVA GLA product line. Management's recently **reiterated guidance of $10 million in revenues**, which would represent record revenues for the company, compares to less than $1.2 million in total revenues in 2019.

Arcadia Biosciences is an **innovative, agricultural biotechnology company** with a broad and growing agricultural product portfolio focused predominately on improving crop traits and nutritional value. Targeted traits include improvements that optimize nutritional and wellness value (like increased fiber and reduced allergenicity), particularly for wheat and soybeans, as well as an optimized cannabinoid profile for hemp. The company **develops seeds for crops**, with the current focus on **hemp, wheat and soybeans** under the trademarked names of **GoodHemp™**, **GoodWheat™** and **Verdeca HB4®** soybeans, respectively. Arcadia Biosciences owns or exclusively controls 153 issued patents and 63 pending patent applications worldwide across 30 patent families.



Product logos from Arcadia Biosciences' website

Furthermore, the **HB4 soybean franchise** offers a **blue sky opportunity** if/when China grants an import license for HB4 soybeans **grown in South America** (primarily Argentina, Brazil, Paraguay and Uruguay).

In 2017, management began transitioning the company from a predominantly agricultural research and licensing company (which targeted revenue from government grants and research contracts) to **branded, agricultural ingredient company** that is striving to **capture a position in the higher margin, branded, plant-based ingredients business** that targets markets higher in the value chain where consumers are willing to pay premium prices, namely in the nutritional, food & beverage, cosmetics, personal care and pet nutrition industries. These markets target the burgeoning growth in demand for differentiated health & wellness products, such as healthy high-fiber food options, specialty low gluten choices and quality CBD products.

The foundation for developing a portfolio of quality ingredients for the consumer market is the company's core competencies in plant genomics and **ArcaTech platform**. Arcadia has a robust and growing library of unique and high-value traits for multiple crops, including wheat and soybeans. Even though the company's first commercial hemp product, **GoodHemp™** (an ultra-low THC, disease resistant hemp seed) **debuted within 11 months**. Arcadia's expertise and technologies allow for rapid development and commercialization of novel traits. The company's advanced gene-editing and breeding capabilities provide significant advantages in terms of both developing quality value-added agricultural products and accelerating the commercialization timetable.

As part of the transition strategy, management has placed enormous importance on the **commercialization process**. Through **joint ventures, partnerships** and collaborations, management has accelerated the speed at which the company's **go-to-market strategy** can be implemented.

In Hawaiian hemp, the joint venture with **Legacy Ventures Hawaii** fast-tracked the 50 acres of hemp cultivation and is advancing the construction of an extraction and processing facility. A partnership with **Vivion Specialties** is expected to generate sales of Arcadia's Hawaiian-grown, hemp-extract CBD products later in 2020. In California hemp, partnerships with **Grow West** and **Buttonwillow Warehouse Company** are anticipated to jump-start sales of the GoodHemp seed line**.**

A plethora of distribution channels are in place for the HB4 Soy line in South America. Through **Verdeca**, a joint venture with **Bioceres Crop Solutions**, licenses for varieties of HB4 soybeans have been allotted to Bioceres Semillas SA in Argentina, Semillas Agronegocios del Plata in Uruguay and Tropical Melhoramento e Genética Ltda. (TMG) in Brazil.

GoodHemp™

Interest in and demand for CBD has exploded since passage of the U.S. Agriculture Improvement Act of 2018, which went into effect on January 1, 2019. Removing hemp from regulation under the Controlled Substance Act has spawned a hemp CBD product industry that is estimated to generate annual revenues of over $20 billion in the U.S. by 2025. The under-researched hemp space is ripe for genetic innovation.

Arcadia has established a 50-acre hemp and hemp seed cultivation footprint in Molokai, Hawaii as well as 10-acre hemp research facilities in California and, through a partner, in Oregon. Within 10 months, Arcadia introduced a GoodHemp seed that produces a disease resistant plant with ultra-low levels of tetrahydrocannabinol (THC). A backlog of $3 million is expected to be ordered and shipped during the second through fourth quarters, and Hawaiian CBD products are expected to come online in the third quarter.

GoodWheat™

Arcadia's GoodWheat portfolio also has a high-fiber variety with up to 10 times the dietary fiber of traditional wheat. In 2019, the company announced that GoodWheat will come to the North American market exclusively through Bay State Milling Company under the rollout of a high fiber wheat bread under Bay State's HealthSense brand. As a sign of Bay State's commitment, in February 2020, Bay State Milling announced the construction of a new 1 million bushel grain storage elevator, which will support the go-to-market plan for the product launch. In the second quarter of 2020, initial GoodWheat revenue should be recorded from shipments to Europe.

HB4® soybeans

Arcadia's Verdeca HB4 drought tolerant soybeans are expected to launch into commercial production in Argentina about a year after China allows for its import. In the meantime, increasing numbers of farmers are registering for field trials. The most recent HB4 pre-commercial soybean crop (slated for harvesting in May 2020) was planted on roughly 2,800 hectares in order to build an inventory of seed for the next cycle. The magnitude of the next crop cycle is expected to be as much as 40,000 hectares based a 1,000% increase in sign-ups for acreage at Argentina's Expoagro held in March 2020.

The company continues to **build investor awareness** by attending **Analyst Conferences**. In 2019, management made presentations at the:

- 15th Noble Capital Markets Annual Investor Conference in Fort Lauderdale (January 28, 2019)
- The Spring Investor Summit in New York City (April 2, 2019)
- 21st Annual H.C. Wainwright Global Investment Conference in NYC (September 10, 2019)

Also, the company holds **quarterly earnings conference calls** that include business updates. Transcripts are available on Seeking Alpha and Yahoo-Finance.

RECENT NEWS

Management Guidance

In late January 2020, management provided **revenue guidance for 2020 of $10 million**, which is expected to be primarily driven by the purchases of the recently introduce GoodHemp product line. The guidance was **re-confirmed on the May 13th** first quarter conference call, after taking into account the effects of COVID-19 pandemic.

Recent Developments - GoodWheat

Arcadia Biosciences continues to enhance the company's wheat platform through **additional patents and Notices of Allowances** granted by the U.S. Patent and Trademark Office.

In late February 2020, the company was awarded a patent for a non-genetically modified (non-GM) yield-improving allele that **improves yield** in high fiber, resistant starch wheat. Multi-year field studies with breeding lines carrying the higher-yielding allele produced an average of 6% to 9% higher yields. The field trials also indicated that the same wheat allele produced a 25% higher yield when the wheat plots were damaged by frost at a sensitive heading stage. The innovation was developed through ArcaTech.

In May 2020, Arcadia Biosciences was granted two patents for **extending the shelf life** of the company's GoodWheat wheat varieties of extended shelf life and reduced gluten by minimizing hydrolytic and oxidative rancidity (U.S. Patent 10,463,051 and 10,457,951). Also, Arcadia received notices of allowance for two additional patents that extend earlier claims on extended shelf life and reduced gluten wheat GoodWheat product lines. Arcadia's patented trait technology **improves the shelf life and taste of whole wheat flour** by slowing enzymatic processes that cause bitterness as it ages. By this means, the storage life of whole wheat flour made with GoodWheat is extended to more than 10 months versus 10 to 30 days for standard whole wheat flour.

Recent Developments - GoodHemp

On January 30, 2020**,** Arcadia Biosciences announced that **over $3 million in initial seed purchase commitments of GoodHemp** had been secured for the 2020 spring plantings since the branded product's debut at the American Seed Trade Association CSS & Seed Expo in mid-December. The $3 million in seed purchases was re-confirmed on the May 13th first quarter conference call. Revenues from these initial purchase commitments should be recognized when the seeds are delivered to growers, which management anticipates being no later than the fourth quarter of 2020.

In January 2020, Arcadia established the **GoodHemp Innovation Partners platform**, a group of select growers who will collaborate with Arcadia's agronomists (breeders, geneticists and computational biologists) in order to advance more quickly and more robustly the understanding and opportunities of GoodHemp seed. **Structured as a hub model**, regional centers are currently located in Hawaii, the Pacific Northwest (Portland), Southern California, Florida, and near the company's headquarters in Davis California. Other centers are planned for the Desert Southwest, Mountain West and Mid-West.

On March 19, 2020 Arcadia Biosciences announced strategic partnerships with two California companies (**Grow West** and **Buttonwillow Warehouse Company**) in order to better and more quickly introduce GoodHemp seeds to hemp growers in California. The grower relationships of these two companies will afford synergies to the process of the GoodHemp Innovation Partners platform and help introduce the GoodHemp seed line to California growers. Grow West is a large independent supplier of agricultural products with 18 retail, farm supply and wholesale manufacturing facilities located primarily in Northern California while Buttonwillow is a family-owned and operated distributor of fertilizer and crop protection products that serves Central and Southern California.



Grow West website



Buttonwillow Warehouse website

In March 2020, Arcadia signed an agreement with **Vivion Specialties** to manage the state-side marketing and sales of Arcadia's Hawaiian-grown hemp-extract CBD products. Along with exclusively distributing Arcadia's Hawaiian-grown THC free distillate and CBD isolate to North American food, beverage, nutrition, personal care and pet markets, Vivion will certify the products under their branded **VivAssure™** ingredient process.

On June 10, 2020, the company announced that a binding term sheet has entered into with **Industrial Seed Innovations**, an Oregon-based industrial hemp breeding and seed company with genetic assets including a germplasm library. Management expects the acquisition to close in the third quarter of 2020.

Industrial Seed's intellectual property, genetics portfolio and customer base will synergistically strengthen Arcadia's hemp breeding and seed production capabilities, along with enhancing the ArcaTech discovery platform. Management expects that the acquisition will be meaningfully accretive to cash flow from operations in 2021.

Recent Developments - HB4®

In November 2019, **regulatory approval** of the **HB4 trait** was **granted by Paraguay**, expanding the number of countries that have approved the sale HB4 drought-tolerant and herbicide-resistant soybeans.

In March of the last two years (2019 and 2020), Verdeca has showcased HB4 drought tolerant soybeans at **Expoagro**, Argentina's largest farm show, which is attended by over 150,000 attendees. During the exposition, Verdeca recruits South American growers to adopt HB4 soybean varieties for the upcoming growing season.



Expoagro

Source: Expoagro Commercial Brochure

The **most recent HB4 pre-commercial soybean crop** (slated for harvesting in May 2020) was **planted on roughly 2,800 hectares** (6,900 acres) to build an inventory of seed for the next cycle. The **magnitude of the next crop cycle is expected to be between 20,000 and 60,000 hectares** (50,000 – 150,000 acres), depending grower appetite for HB4 technology.

First Quarter 2020 Financial Results

On May 13, 2020, Arcadia Biosciences reported financial results for the first quarter ending March 31, 2020. **Total revenues increased 95.6%** to approximately $309,000 Product revenues (mostly sales of SONOVA products, along with initial GoodWheat seed sales) increased 43.9% to approximately $154,000, primarily driven by strength in SONOVA encapsulated orders. License revenues were $100,000 compared to no revenues in the comparable period last year. Royalty revenues were $30,000. Contract research and government grant revenues decreased 51.0% to $25,000. Since management to pursuing sales opportunities of GoodWheat and GoodHemp products, contract research agreements and government grant projects are no longer being pursued.

Cost of product revenues increased 124% to approximately $132,000, due the increase in product revenues and a write-down of wheat inventory. R&D expenses increased 49.1% to approximately $2.24 million, primarily higher employee-related expenses from expanding the hemp research team. SG&A expenses increased 32.4% to approximately $3.72 million, primarily driven by higher consulting and employee-related expenses.

For the first quarter, Arcadia Biosciences reported a net gain of $2.525 million (or $0.29 per diluted share), of which $8.161 million was related to the change in fair value of stock warrants, a non-cash item. Without this non-operating item, Arcadia's operating loss was $5.636 million (or $0.65 per diluted share).

As of March 31, 2020, working capital was approximately $17,950,000, which slightly declined sequentially from approximately $22,732,000 on December 31, 2019. Shares outstanding increased slightly by 0.1% to 8,654,095 shares, sequentially.

PPP Loan

On April 16, 2020, Arcadia Biosciences entered into a 2-year, 1% unsecured note in the amount of $1,107,700 under the Paycheck Protection Program (PPP), which was established under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). Since the proceeds of the note will be used for payroll costs, mortgage interest, rent and utilities, management anticipates applying for forgiveness of the loan granted under the PPP. The lender is MidFirst Bank.

OVERVIEW

Headquartered in Davis, California, Arcadia Biosciences, Inc (NASDAQ: RKDA) is an **innovative agricultural biotechnology company** with a broad and growing agricultural product portfolio focused predominately on improving crop traits and nutritional value, which thereby enhance end-market (consumer packaged food and health & wellness companies) demand as well as farmer productivity. Targeted traits include crop yield, efficiency of nitrogen use, efficiency of water use and tolerances to drought, salinity and herbicides. The company **develops seeds for crops**, with the current focus on **hemp, wheat and soybeans** under the trademarked names of **GoodHemp™**, **GoodWheat™** and **Verdeca HB4®** soybeans, respectively. Arcadia Biosciences owns or exclusively controls 153 issued patents and 63 pending patent applications worldwide across 30 patent families.

The company utilizes five science-based approaches to develop high-value crops through plant breeding and gene-editing technologies. This proprietary, rapid prototyping R&D technology platform, dubbed

ArcaTech, facilitates the rapid development of innovative agricultural ingredient products with novel tolerance, nutritional and/or reduced allergen traits.



- **Genomics** (design)
  - using sequencing technology to map and analyze plant genomes, plant breeding programs can be efficiently optimized by identifying superior gene targets
- **TILLING** (Targeting Induced Local Lesions IN Genomes)
  - TILLING technology analyzes DNA samples for allele (genes on a chromosome that determine hereditary characteristics). The low-cost process facilitates the rapid discovery of novel alleles, which can be developed into commercially-viable, differentiated agricultural products.
- **CRISPR Cas-9** (Clustered Regularly Interspaced Short Palindromic Repeats Cas9)
  - the in-licensed CRISPR Cas9 gene-editing platform helps accelerate the pace of research by enabling rapid trait discovery
- **Phenotyping** (test by measuring attributes)
  - a process of measuring and testing the characteristics that result from gene changes produced through controlled breeding programs
- **Conventional plant breeding and field evaluation** (breeding)

Arcadia's breeding capabilities and advanced gene-editing technologies facilitate and expedite the development of proprietary innovations of crop's genome, which are then patented and advanced to commercialization. High-value traits (such as improved crop yields, nutrition, etc.) deliver agricultural products with improved attributes that allow branded companies to differentiation their product offerings. Management plans on monetizing the novel discoveries through sales of seed, grain and product extract as well as through trait licensing and royalty agreements.

MANAGEMENT'S GROWTH STRATEGY

Since 2017, management has strived to develop healthy food options and value-added, differentiated agricultural products that **target the demand from consumer food and health/wellness companies**. In addition, management has placed a greater importance on time-to-market to satisfy current consumer demand. As a result, **the bulk of Arcadia's revenue has transitioned** from contract research agreements and government grants **to product sales** as a result of management's strategy to **emphasize the commercialization of the ingredient traits** of the company's agricultural products, particularly in the company's three strategic crop categories: **wheat, soybeans and, most recently,**

hemp. By moving to the value-added end of the food chain, Arcadia is positioned to address the lucrative, less price-sensitive and higher margin portion of the agricultural value food chain.

Arcadia Biosciences, Inc.	Percentage of Revenues		
Segments	Year ending 12/31/2017	Year ending 12/31/2018	Year ending 12/31/2019
Product	12.8%	44.9%	69.6%
License	36.5%	10.2%	5.7%
Contract research & gov't grants	50.7%	44.9%	24.6%

Historically, Arcadia was dedicated to the development of abiotic stress traits with a focus on enhancing crop robustness (quality, resiliency and yield) and on improving yields. The effort was focused primarily on farmers (growers). Through 2017, licensing and contract research & government grants accounted for the vast majority of revenue (over 80%). While the company had some success, the shift in regulatory and consumer attitudes **away from genetically modified (GM) foods** provided an opportunity for management to leverage Arcadia's technologies and industry relationships **towards the non-GM space** and shift the company's focus on branded consumer food companies.

The shift in strategy was facilitated by the adoption of additional technology, which was bolstered in 2017 with the in-licensing (from MIT and Harvard University) of **CRISPR-Cas9** gene-editing technology. CRISPR-Cas9 complements Arcadia's **TILLING platform**. Used in combination, the two technologies are expected to significantly reduce the time to bring novel discoveries to market. TILLING functions as a way to create seed and DNA libraries by identifying certain attractive mutations in specific genes while CRISPR-Cas9 allows for direct gene-editing of a crop's DNA with the goal of enhancing attractive traits. The combination of TILLING and CRISPR-Cas9 is estimated to reduce time-to-market of a novel discovery by approximately two years to three-to-five years versus TILLING alone, which generally was five-to-seven years.

Management is in the process of **migrating the company's commercial strategy** in the agricultural food supply chain from farmers **to consumer food companies**. Arcadia is transforming into an agricultural ingredient company that **targets the demands of consumer food and health & wellness product markets**. Current consumer demand is shifting towards **natural, healthier and more nutritional food** options.

An increasing amount of future sales should be derived from food and other products (such as hemp) that incorporate proprietary traits that Arcadia Biosciences has developed. The needs of farmers will continue to be addressed through superior crop attributes while Arcadia is targeting the premium economics in the end-markets of the agricultural food supply chain.

Also, management is refining the company's **go-to-market strategy** that entails aligning with the branding strategy of food companies by providing high-value food ingredients that enable branded packaged food companies to differentiate their products in the marketplace.

Arcadia's **high-visibility development initiatives** include:

1) **GoodHemp™**
    - The 2018 Farm Bill creating a burgeoning market by essentially de-scheduling hemp and hemp-derived products from the Controlled Substance Act
    - Formed **Arcadia Specialty Genomics** unit in February 2019 with growth chamber facilities and greenhouses located in Central California
    - Formed **Archipelago Ventures Hawaii, LLC joint venture** with **Legacy Ventures Hawaii** in August 2019 with plans to build world class cGMP extraction facilities in Hawaii
    - Launched GoodHemp seed in December 2019

2) **GoodWheat™** - portfolio of specialty wheat varieties
   - In 2019, introduced **resistant starch GoodWheat** and **high fiber GoodWheat**
   - In 2020, launched **reduced gluten GoodWheat**
   - Introduction of **high fiber durum** expected later in 2020
   - Collaboration with millers/trait companies:
     - **Ardent Mills LLC** in November 2018 for improving the flavor profile and shelf-life
     - **Bay State Milling** in August 2019 for high fiber GoodWheat in North America
     - **Arista Cereal Technologies** in December 2019 for high fiber GoodWheat in Asia, Australia and Europe

3) **Verdeca HB4®** drought tolerant and herbicide tolerant soybeans
   - **Verdeca LLC joint venture** with **Bioceres**, a major Argentinian agricultural bio-technologies (crop and seed trait) company
   - **HB4** and herbicide tolerant trait stack have received regulatory approvals in the U.S., Brazil, Argentina and Paraguay
   - Introduction of drought resistant soybeans expected later in 2020

Arcadia Biosciences strives to improve the quality and nutritional value of plant-based ingredients by directing the company's **core competencies in plant genomics** (through its ArcaTech platform) to rapidly develop innovative new varieties of crops, particularly for the species of wheat, soybeans and now hemp. **In 2019, hemp became a new strategic crop for Arcadia**. A pipeline for commercialization has been developed, including a catalog of multiple varieties and the development of six novel varieties that are expected to be evaluated in on-farm trials during 2020.

GoodHemp™

In February 2019, management announced that the company would be pursuing the genetic improvement, development and commercialization of a new crop: **hemp**. A new strategic business unit, **Arcadia Specialty Genomics** (ASG), was established to spearhead the effort. Since ASG intends only to conduct business in markets where the agricultural product is legal on a federal and state basis, initially the unit is **focused on hemp** (a non-psychoactive strain of the cannabis plant), which was federally legalized through the U.S. Agriculture Improvement Act of 2018. The company's first commercial hemp product, **GoodHemp™** (an ultra-low THC, disease resistant hemp seed) **debuted within 11 months**, demonstrating Arcadia's prowess for innovation (via the ArcaTech platform) and speed-to-market capabilities, particularly though adept partnering abilities.

GoodHemp™ Milestones

- February 2019 – announced formation of **Arcadia Specialty Genomics** business unit
- March 2019 - granted an **Industrial Hemp Pilot Program License** in Hawaii
- April 2019 - opened sun-grown **cultivation** facility in Hawaii
- August 2019 – formed **Archipelago Ventures Hawaii**, LLC JV with Archipelago™ Ventures
- September 2019 - granted a **Hemp License** in California
- December 2019 – launched **GoodHemp™** and produced first **seed catalog**
- January 2020 - formed **GoodHemp Innovation Partners platform**
- March 2020 - partnered with **Grow West**® and **Buttonwillow Warehouse** Company
- March 2020 - partnered with **Vivion Specialties** to distribute Hawaiian hemp-derived products in North America

Management's Hemp Strategy

Due to the Federal legal restrictions on hemp as a controlled substance prior to 2019, very little genetic research was conducted on hemp. Consequently, the quality of CBD hemp seed was uneven, resulting in unpredictable crop outcomes. Given the lack of advancements in genetics of the hemp plant, vast agricultural and financial opportunities lie before Arcadia. **Management's goal in the hemp space is to develop proprietary, genetically-improved hemp seeds and hemp-derived CBD products for the commercial market** and position the company as a premier provider to meet the upcoming wave of demand for hemp seeds, transplants, flower and extracts for the nutraceutical, personal care and food industries.

As part of an aggressive germplasm acquisition strategy, Arcadia acquired strains of hemp germplasm in early 2019, and by July 2019, Arcadia's hemp breeding program internally created the company's first proprietary hemp variety. In December 2019, Arcadia introduced **Complia™ Bot+**, the company's first hemp strain that provides a high 10%+ CBD content with an ultra-low THC content. These milestones demonstrate Arcadia's expertise in **plant genetics** and **competencies in varietal development**. By May 2020, **10 varieties** of the Complia hemp product line had been developed and were available for plantings.



Arcadia Biosciences Corporate Presentation April 2020

The next stage is to develop a robust, proprietary seed portfolio with novel crop traits related to crop quality, pest resistance, climate resiliency and yield. Management is especially eager to broaden the breadth of the strains that will flourish under diverse geographical and climatic settings, such as Hawaii's, California's, the Pacific Northwest and Florida's unique climates.



Arcadia is leveraging **ArcaTech** to help rapidly develop varieties of hemp. The company acquired strains of hemp germplasm to **quickly go-to-market** with the Complia Bot portfolio of seeds. Through the acquisition, Arcadia's scientists were also able to rapidly **develop a library of germplasm** that contain genetic variations which can **fuel a robust breeding pipeline via the proprietary ArcaTech prototyping technology platform**. Longer-term, management expects to develop varieties designed for industrial hemp fiber and nutritional hemp protein markets.

Management expects the number of varietal offerings in the company's seed portfolio to significantly expand as the company's technology platform develops improved hemp traits through genetic optimization and the company's breeding operations verify the expected improved performance claims.



Cultivation Facilities

In March 2019, Department of Agriculture of Hawaii granted an **Industrial Hemp Pilot Program License**, which allows for the cultivation of industrial hemp in **Hawaii** for the purposes of agricultural and academic research. In April, Arcadia opened a 10-acre sun-grown **cultivation facility** on leased land in Molokai and began its research program, which is focused on the development of novel varieties and crop quality traits that will enhance pest resistance and possessing productivity. Management's plans are to produce proprietary seed lines and flower for cannabidiol (CBD) oil extraction.

Within five months, the cultivation footprint was expanded to 30 acres and now, in May 2020, an additional 20 acres are coming on line, bringing the total to **50 acres**. Initial harvests demonstrated that several hemp varieties can be successfully grown and harvested over multiple production seasons for CBD production. The next phases of development are the ramp-up of acreage for flower production and the construction of extraction and processing facilities.

Arcadia Biosciences Hemp Growing Fields in Hawaii



Arcadia Biosciences April 2020 newsletter, The Messenger

In September 2019, Arcadia announced plans to open **second sun-grown hemp research and cultivation facility** in **California**. Arcadia registered (on a county level) to cultivate hemp at several locations in Brawley, Imperial County, and within a month, a **10-acre cultivation footprint** was established as a research field station. This is in addition to the company's 25,000-square-foot indoor-growth research breeding greenhouse in Woodland near the company headquarters in Davis.

In the fourth quarter of 2019, Arcadia partnered with a research company in **Oregon**, and a hemp research facility was established to conduct field research in the Pacific Northwest, a key region for the cultivation of cannabis and hemp. Currently, Arcadia has operational hemp cultivation locations in three geographies for the production of hemp and hemp seed.

Joint Venture – Hawaii (Archipelago Ventures Hawaii)

As part of Arcadia's development and go-to-market strategy, the company pursued partnership in order to accelerate the effort to develop and commercialize the hemp-based product initiative. In August 2019, the **Archipelago Ventures Hawaii** joint venture was formed **with Legacy Ventures Hawaii LLC** as a platform to create of a complete seed-to-sale, vertically integrated supply chain. Legacy Ventures Hawaii LLC is a consortium of native islanders supported by equity partner, Vapen CBD. The Archipelago JV is the vehicle by which **Arcadia's genetic expertise** is linked with **Legacy Venture's demonstrated extraction and sales capabilities** to create a comprehensive CBD supply chain. **Vapen CBD** (which has experience in all aspects of cultivation, extraction and manufacturing) is in charge of the construction and operation of Archipelago's cGMP extraction facilities, which are designed to deliver high-grade extract for use in premium CBD products. In addition, Vapen CBD has an established website marketplace (vapencbd.com) that offers a variety of branded CBD products to both retail and wholesale distribution accounts. Vapen CBD emphasizes the organic nature and purity of its ingredients in order to achieve critical product differentiation and competitive advantages. Vapen CBD is a wholly owned subsidiary of Vext Science Inc. (CNX: VEXT; OTCQX: VEXTF), which was formerly known as Vapen MJ Ventures.

***Strategic Partnership - Hawaii (*Vivion Specialties, Inc.)**

In March 2020, Arcadia signed a partnership agreement with **Vivion Specialties** to manage the state-side marketing and sales of Arcadia's **Hawaiian-grown, hemp-extract CBD products**. Later this year, after certification under Vivion's **VivAssure™** process, Arcadia's premium, sun grown, Hawaiian hemp-derived products will be marketed as purity-validated, hemp-derived CBD in North American.



Vivion has a special hemp product process and marketing program that emphasizes CBD ingredient transparency and quality control. Not only are cannabinoid products purity validated under the VivAssure process, but also the precise cannabinoid profile and THC content are included in the details of the Certificate of Analysis. To quote from Vivion's website, "VivAssure™ Cannabinoids are derived from industrial hemp that is legally registered with the United States Department of Agriculture and conforms fully to the 2014 US Farm Bill section 7606." [i]

Founded in 1957, Vivion Specialties, Inc. is a specialty ingredient supplier that **certifies and distributes ingredients** for the nutritional, pharmaceutical, food & beverage, cosmetics, personal care, pet nutrition, agricultural chemical and industrial markets through a network of 18 sales regions in the U.S. and Canada. In addition, Vivion certifies products under their branded **VivAssure** ingredient purity validation process, which tests products "for 950 pesticides and contaminants, 24 heavy metals and a variety of microbial organisms."[ii] Each VivAssure tested product is shipped with a detailed Certificate of Analysis.

Strategic Partnerships – California (Grow West and Buttonwillow Warehouse Company)

In March 2020 Arcadia Biosciences entered into strategic partnerships with two California companies (**Grow West®** and **Buttonwillow Warehouse Company**) in order to better and more quickly introduce GoodHemp seeds to hemp growers throughout California. The grower relationships of these two companies will **afford synergies for the promotion of the GoodHemp seed line to California growers**. California hemp farmers rely on companies with agricultural expertise, like Grow West and Buttonwillow Warehouse, for advice on important decisions throughout the growing season, such as seed product selection, crop fertilizer alternatives and pest control choices. In 2019, hemp was cultivated on over 17,000 acres in California.

These two retail companies will **contribute to the Innovation Partners platform**, which is designed to advance the commercialization of GoodHemp. Through the California hubs, Grow West and Buttonwillow will convey to the platform the knowledge gleaned from their personal relationships with growers, which will provide unique insights of the California hemp cultivation market with its unique climate and production practices.

Based in Woodland, **Grow West®** is a large independent supplier of agricultural products with 18 retail, farm supply and wholesale manufacturing facilities located primarily in Northern California.

With over 11 retail locations, **Buttonwillow** is a family-owned and operated distributor of fertilizer and crop protection products that serves Central and Southern California.

Regulatory Background on Hemp

The U.S. Agriculture Improvement Act of 2018 (aka the Farm Bill) redefined hemp as an agricultural product, thereby opening a potentially enormous new agricultural commodity market in the U.S. Previously, the Farm Bill of 2014 legalized hemp for state-sanctioned research programs; however, the **Farm Bill 2018 completely removed hemp from regulation under the Controlled Substance Act** thereby declassifying hemp as a Schedule 1 drug. Specifically, the Farm Bill (which went into effect on January 1, 2019) separated the definition of hemp from that of marijuana and defined hemp as the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not with a delta-9 tetrahydrocannabinol concentration of not more than 0.3% on a dry weight basis. As a result, the cultivation of the hemp plant is no longer illegal under U.S. federal statutes, though individual states are still able to regulate hemp.

Hemp and CBD Markets

Deregulation and increasing awareness of the potential health and well-being benefits of CBD is expected to drive growth in consumer spending on CBD products and increase the use of CBD in medical applications. Market researchers delineate the markets in various ways, from the domestic hemp-derived CBD (Brightfield Group)[iii] to the global CBD market (Fior Markets)[iv]. **Compound annual growth rate** (CAGR) **forecasts** over their respective forecast periods **range from 15.8%** by Grandview Research **to 36.3%** from Fior Market. Other firms providing forecasts are the Hemp Business Journal (hemp CBD market), Grandview Research (non-cannabinoid industrial hemp), ResearchAndMarkets[v] (Global Industrial Hemp) and 360 Research (Cannabidiol). Nevertheless, the forecasted growth rates are in the **strong double-digit range**, which **should drive significant demand for hemp seeds**, transplants, flower and extracts, particularly genetically superior hemp products developed by Arcadia Biosciences.

Hemp Catalog

Arcadia Biosciences introduced a **GoodHemp seed catalog** in December 2019. The first variety in the catalog was **Complia™ Bot+**, a strain that provides a high 10%+ CBD content with an ultra-low THC content. The catalog quickly expanded to five seed offerings, and by May 2020 the selection had increased to **10 varieties** of the Complia hemp product line.



Arcadia Biosciences Corporate Presentation April 2020

GoodHemp Innovation Partners Go-To-Market platform

In January 2020, Arcadia established the **GoodHemp Innovation Partners platform** in order to provide additional support to the GoodHemp product line and accelerate the go-to-market process. Structured in **regional hubs**, select growers and distribution partners collaborate with Arcadia's agronomists (breeders, geneticists and computational biologists) and act as a hemp production advisory board in order to **obtain insights** into the challenges that are faced by growers, along with the best practices employed by them. In addition, Arcadia's agronomists should gain better understandings into the

opportunities for GoodHemp that could guide the genetic development programs. In turn, growers participating in the Innovation Partners platform will have early access to new, developmental hemp varieties.

The current hubs are located in Hawaii, the Pacific Northwest (Portland), Southern California, Florida, and Central California (Davis). Other centers are planned for the Desert Southwest, Mountain West and Mid-West.

Near-term Outlook for Hemp Initiative

Over the near-term, Arcadia is expected to benefit the production and sale of select varieties of hemp seeds designed for specific geographic regions in California. The company has received over $3 million worth of orders for early adopter farmer trials in the April/May planting season. Demand was aided the regulatory mandate from the USDA requiring "hot" crops (those that exceed 0.3% THC) be destroyed. In 2019, approximately 20% of U.S. hemp crops (50,000 acres of 230,000 acres planted worth roughly $2 billion)[vi] were deemed non-compliant.

Management anticipates that **sales of hemp extract and CBD products** will begin in the third quarter, driven by the construction of an extraction and processing facility in Hawaii and Vivion's certification and distribution of Arcadia's CBD ingredients.

GOODWHEAT™

One of the company's flagship proprietary product programs is the **GoodWheat brand**, which is comprised of non-genetically modified (non-GM) varieties of wheat with enhanced attributes. Management is committed to expanding the GoodWheat platform and accelerating its commercialization. Over the last few years, Arcadia Biosciences has introduced several varieties of GoodWheat and entered into strategic collaborations with millers to advance the distribution of consumer products made with GoodWheat.

GoodWheat resistant starch contains very high levels (up to 94%) of amylose. This significant value-added trait **delivers high dietary fiber content**, which can promote gastrointestinal health and relieve obesity-related health conditions. Concurrently, Arcadia reported that GoodWheat resistant starch delivers the high levels of dietary fiber which meet the U.S. Food and Drug Administration's (FDA) threshold for the designations of "**good source of fiber**" and "**high in fiber**" on consumer packaging, increasingly important attributes desired by both consumers and food companies.

The average American's daily diet includes approximately 500 calories from wheat products, which is equal to roughly 25% of the FDA's total recommended caloric intake for women and 20% for men. Consumers are placing increased importance on fiber-rich grain foods as they are becoming increasingly aware of the overall health benefits of resistant starch, including weight loss. These consumer preferences are helping to accelerate demand growth of resistant starch products in general and to expand the size of the potential market for the GoodWheat brand in particular. According to Mordor Intelligence, the global food fiber market is estimated to expand at a 9% CAGR over the forecast period (2019 - 2024) to nearly $88 billion in 2024.[vii] The addressable U.S. market for GoodWheat is estimated to be as much as $9.7 billion.

High fiber GoodWheat resistant starch, with its high levels of amylose resistant starch, increases the total dietary fiber content without the need for the addition of fiber additives. According to MarketsandMarkets, the **global dietary fibers market** is projected to reach $9.6 billion by 2025, up from an estimated $5.3 billion in 2020[viii] (12.5% CAGR) due to increased demand for plant-sourced fiber products and supplements that stems from the growth in health concerns and gastrointestinal disorders, along with an increasing vegan population.[ix] Our estimate growth rate is slightly more conservative at an 11.3% CAGR.



In addition, non-genetically modified (non-GM) foods have other inherent advantages over their genetically modified counterparts. According to the Pew Research Center, GM foods are being viewed negatively by a sizable minority with 39% of Americans believing that GM foods are less healthy than regular foods.[x]



The same study indicates that a majority of U.S. consumers believe that organic foods are more health than conventionally grown produce. As a result, the growth of organic foods is significantly outpacing that of non-organic foods. According to the Organic Trade Association's 2019 Organic Industry Survey (released in May), organic food sales continue to outpace the general market, with sales increasing 5.9% in 2018 compared to just 2.3% for total food sales.[xi] Foods labeled as organic cannot contain GM products. This mega-trend of increasing demand for organic foods is another catalyst for the GoodWheat portfolio.

Total U.S. Organic Sales & Growth, 2009–2018

CATEGORY	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Organic Food	21,266	22,961	25,148	27,965	31,378	35,099	39,006	42,507	45,209	47,862
Growth (%)	4.3%	8.0%	9.5%	11.2%	12.2%	11.9%	11.1%	9.0%	6.4%	5.9%

SOURCE: ORGANIC TRADE ASSOCIATION'S 2019 ORGANIC INDUSTRY SURVEY CONDUCTED 1/25/2019–3/26/2019 (CONSUMER SALES).

Furthermore, non-GM foods are, in general, less costly to prepare and, in the U.S., require less time-consuming regulatory oversight. Some markets in Europe and Asia have banned GMO foods.

Arcadia Biosciences markets its GoodWheat line of products through demonstrations and sampling of pasta, waffles and desserts, such as at the International Baking Industry Exposition that was held from September 7 to 11, 2019 in Las Vegas.

GoodWheat variety milestones

- March 2018 - GoodWheat **resistant starch** achieves up to 94% of amylose
- April 2018 - introduced GoodWheat **reduced gluten** (overall gluten content reduced of 60%)
- October 2018 - GoodWheat **extended shelf life** wheat granted U.S. Patent No. 10,087,455
- November 2018 - harvest on almost 230 acres of GoodWheat **resistant starch** & 1st field production **reduced gluten**
- 2019 - GoodWheat **resistant starch** introduced
- 2019 - GoodWheat **reduced gluten** introduced
- November 2019 - harvest of GoodWheat varieties on 2,300 acres in ID, MT, ND, OR & AZ
- December 2019 - limited release of **reduced gluten** GoodWheat flour
- May 2020 - GoodWheat **extended shelf life** & **and reduced gluten** granted additional two U.S. patents for extending the shelf life of whole wheat to more than 10 months



GoodWheat website: eatgoodwheat.com



Photo: Arcadia Biosciences, Inc.

During 2019, Arcadia scaled up production of GoodWheat wheat varieties, harvesting winter and summer **trials planted on more than 2,300 acres** in key wheat growing areas. The crops supplied Arcadia with a sufficient material to meet the company's grain and seed supply needs to attain management's targets for 2020 sales. **In the fourth quarter of 2019, Arcadia delivered its first seed sales to Bay State Milling** for the counter-season planting. However, harsh weather and an increase in disease across the upper Midwest reduced the initial sale by approximately $250,000. Nevertheless, on February 18, 2020, **Bay State Milling announced the construction of a new 1 million bushel, grain storage elevator** at its Tolleson Arizona location in order to support the go-to-market plan for the rollout of Arcadia's high fiber GoodWheat under the HealthSense brand.

In December, Arcadia rolled out a **limited release of reduced gluten GoodWheat flour**; the limited supply sold out by the end of January. Since early December, five new consumer packaged goods (CPG) companies have begun evaluating GoodWheat in beer, pasta and bread products. Announcements concerning of the use of GoodWheat varieties by specific consumer food companies in 2020 would give confidence that management's revenue expectations would be achieved this year.

During 2020, management expects commercial sales of high fiber GoodWheat (both resistant starch and reduced gluten) to scale up as the company continues to build partnerships across the wheat value chain and work with multiple public breeding platforms. This effort has been bolstered by GoodWheat resistant starch having met the FDA's requirement for the designations of "high in fiber" and "good source of fiber."

According to the company's newsletter, The Messenger, growing conditions for GoodWheat varieties in the field are very good with the harvest in the southern U.S. expected in the May-June range. The spring planting in the northern U.S. is on schedule. As of April, 70% of the contracted acres planted.

GoodWheat Strategic Collaborations

A global commercial agreement among Arcadia Biosciences, Arista Cereal Technologies and Bay State Milling was formalized in December 2019. The milestone event provided the infrastructure basis towards commercializing high fiber GoodWheat resistant starch in North America, Europe and Australia. The agreement secures go-to-market pathway for high fiber GoodWheat to enter the North American market under Bay State's HealthSense™ branded flour. An initial purchase commitment was secured from Bay State Milling for bread wheat for delivery in 2020.

- November 2018 - collaboration with **Ardent Mills** to develop and commercialize GoodWheat varieties
- August 2019 - binding term sheet agreement with **Arista Cereal Technologies** resolved patent dispute
- December 2019 - **Bay State Milling** becomes exclusive North American commercial partner for high-fiber bread GoodWheat under Bay State Milling's HealthSense™ flour brand

Collaboration with Ardent Mills - 2018

On November 6, 2018, Arcadia Biosciences announced a **collaboration with Ardent Mills** LLC, a leading North American flour-milling and grain-based ingredient company with over 35 community flour mills and mixing facilities in the U.S., Canada and Puerto Rico. The relationship is focused on advancing the development and commercialization of innovative wheat varieties, initially on Arcadia's extended shelf life and flavor improvement programs that utilize the company's proprietary non-GM wheat genetic diversity TILLING library. Arcadia's trait technology can **extend the storage life of whole wheat flour** by slowing enzymatic processes; the slower oxidation concurrently **diminishes the bitterness** associated with many whole wheat products, thereby improving the taste of the resultant consumer products.

Collaboration between Arcadia, Arista Cereal Technologies and Bay State Milling - 2019

In August 2019, Arcadia entered into a binding term sheet with Bay State Milling Company and Arista Cereal Technologies in order to resolve a patent dispute. Later, the relationship was formalized in December 2019, when a global collaboration agreement was signed. Arista Cereal Technologies (a joint venture company formed by the French farmer cooperative Limagrain and Australia's Commonwealth Scientific and Industrial Research Organization), received the exclusive rights of Arcadia's high fiber wheat IP (intellectual property) in Australia and Europe, while **Bay State Milling Company** became Arcadia's **exclusive commercial partner for high fiber GoodWheat in North America**. Bay State, which strategically is emphasizing distinctive plant-based ingredients for the next generation of sustainable and healthful foods, will utilize high-amylose GoodWheat under in its branded **HealthSense™ flour**.

SONOVA® GLA SAFFLOWER OIL

SONOVA GLA safflower oil was developed under a licensing agreement with Abbott Laboratories (NYSE: ABT). The primary active component of SONOVA GLA is gamma-linolenic acid (GLA), which is an omega-6 fatty acid found in a very few plant-based oils (e.g. borage, evening primrose, black currant, and safflower). **SONOVA GLA contains the highest concentration of GLA (65%)** compared to other conventional plant oils that only contain between 10% and 22%. Clinical evidence indicates that **GLA has proven anti-inflammatory, skin health and anti-aging benefits** in humans[xii] and also in dogs and cats.

Acadia contracts farmers in Idaho to produce GLA safflower and then contracts a manufacturer in California to process the seed into refined oil. Acadia sells its branded SONOVA GLA safflower oil in the United States in multiple concentrations (40%-65%) and formulations, primarily to manufacturers of dietary supplements, nutritional supplements, medical foods and dog food. Acadia Biosciences continues to receive interest from additional potential customers that are looking to incorporate SONOVA GLA safflower oil into their products.

Over the long term, sales of SONOVA GLA are expected to increase in the mid-to-single digit range. However, management does not view SONOVA GLA oil as a large growth opportunity, but rather sees blue sky growth potential in hemp, non-GM wheat and drought tolerant soybeans. Yet, **the company's innovation and development processes that brought SONOVA GLA safflower to market demonstrates that Arcadia has the technological, regulatory and commercialization abilities to advance GoodHemp, GoodWheat and HB4 soybeans**. Acadia Biosciences developed and commercialized SONOVA GLA safflower oil in less than six years.

Development & Commercialization Timeline of SONOVA GLA Safflower Oil

2003	began development of trait under a research & commercial agreement with Abbott Labs
Nov. 2005	research achieved 35% GLA in the oil from safflower seeds
April 2006	research achieved 65% GLA in the oil from safflower seeds
Dec. 2009	received FDA approval of SONOVA 400 GLA for use as a human dietary supplement
Oct. 2010	commercially introduced SONOVA 400 GLA safflower oil (40% GLA)
June 2014	commercially introduced Sonova Ultra GLA safflower oil (55% GLA)
Jan. 2017	FDA grants GRAS petition (generally recognized as safe) for use of SONOVA GLA in medical foods and nutritional beverages
Aug. 2017	FDA approved the use (safe and nutritious) of SONOVA GLA in dog diets
Feb. 2019	FDA approved the use of SONOVA GLA in cat food

HB4® SOYBEANS

In February 2012, Arcadia Biosciences partnered with Bioceres Crop Solutions Corp. (NYSE: BIOX) to form **Verdeca LLC**, a U.S.-based 50/50 joint venture company. Verdeca is focused on the development and deregulation of **genetically modified (GM) drought tolerant soybeans**. The JV's flagship product is HB4® drought tolerant soybeans stacked with herbicide tolerant traits, which provide a yield advantage over conventional soybeans when grown under the same suboptimal conditions. These proprietary, genetically modified soybeans have successfully **undergone extensive validation and regulatory field trials**, which were completed at multiple locations in Argentina and the United States. Importantly, field trials in 2018 were conducted during drought conditions, which especially demonstrated the benefits of the HB4 drought tolerant trait, validating HB4's value proposition.

HB4 Stress Tolerant Soybean Field Trial



Arcadia Biosciences Investor Presentation December 2016

Arcadia Biosciences' partner, **Bioceres** (NYSE: BIOX) is an Argentinian-based fully-integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, high-value adjuvants and fertilizers. Not only does Bioceres hold a desirable trait portfolio, but also **Bioceres is headquartered in Argentina**. The demand for HB4 soybeans may be the greatest in certain places of the world that are prone to arid growing seasons, such as specific regions of South America, particularly Argentina, the third largest soybean exporter in the world. Together, Argentina and Brazil produce over 45% of the world's soybeans; Verdeca has received regulatory approvals for HB4 in both of these South American countries.

The Verdeca JV has advanced the HB4 drought tolerant trait stacked with herbicide tolerant traits, having **received regulatory approvals for the traits and for commercialization (planting and harvesting) in Argentina, the United States, Brazil and Paraguay**, which together account for over 80% of global soybean production.

China would be a meaningful market for South American soybean producers if import approval is granted. The growing middle class population in China has increased demand for soybeans as an affordable protein source. In addition, the recent trade was between the U.S. and China has prompted China to seek alternative sources in order to reduce its dependence on U.S. soybean exports. Import approval was sought from China in 2017. The application continues to be under review, and management is hopeful that the approval may be obtained in late 2020. If import approval is received from China, Argentina could provide a significant revenue opportunity for Arcadia Biosciences through its Verdeca JV.

HB4® Soybean Regulatory Approvals

In order to plant, harvest and sell HB4 soybean products, regulatory approvals are required for food safety and commercialization. In addition, for international commerce, an import approval is required in the country to which the soybean product will be consumed. **The Verdeca JV has advanced the HB4 drought tolerant trait stacked with herbicide tolerant traits through the regulatory submission and approval in Argentina, the United States, Brazil and Paraguay**. The HB4 drought tolerant and herbicide tolerant traits now has **regulatory approval in over 80% of the soybean market worldwide**. Regulatory studies are under way in Europe.

Argentina

- October 2015 – received regulatory approval from Argentina's Ministry of Agriculture, Livestock and Fisheries for HB4 stress tolerance trait
- October 2018 - received approval from Argentina's Secretariat of Food and Bioeconomy for HB4 soybeans with drought tolerant trait stacked with herbicide tolerant traits

United States

- August 2015 – U.S. Food and Drug Administration (FDA) completes the Early Food Safety Evaluation process for HB4 stress tolerance trait
- August 2017 - received U.S. Food and Drug Administration (FDA) approval of HB4 drought tolerant soybeans for commercial use in human food and animal feed
- August 2019 - received U.S. Department of Agriculture (USDA) approval for commercialization (planting and harvesting) of HB4 soybeans (for both tolerant and herbicide tolerant traits)
    - Verdeca may now begin evaluating potential U.S. germplasm partners for the HB4 trait

Brazil

- July 2015 - announced a collaboration with Tropical Melhoramento e Genética Ltda. (TMG), a Brazilian soybean and cotton breeding company, to help develop and commercialize HB4 soybeans with stress tolerance trait in Brazil
- May 2019 - received approval from Brazil's National Technical Commission of Biosafety for commercialization (planting and harvesting) of HB4 soybeans (for both drought tolerant and herbicide tolerant traits)

Paraguay – soybean crop grown on over 3.5 million hectares

- November 2019 - received approval from the Paraguayan Minister of Agriculture (via the National Commission for Agricultural and Forestry Biosafety) for commercialization (planting and harvesting) of HB4 soybeans (for both drought tolerant and herbicide tolerant traits)

The **most recent HB4 soybean crop** (slated for harvesting in May 2020) was **planted on 3,000 hectares** to build an inventory of seed for the next cycle. The **magnitude of the next crop cycle is expected to be between 20,000 and 60,000 hectares**, depending grower on appetite for HB4 technology.

Regulatory applications have also been submitted and are under consideration in Bolivia and Uruguay. **Import applications are under review in China**, Canada, Bolivia and Uruguay. Management expects that an application for regulatory approval in the European Union will be submitted later in 2020.



China is both the leading consumer and importer of soybeans, accounting for roughly one-third of global consumption and 62% of world imports in 2017.[xiii] Once import approval is secured in China, Arcadia's management anticipates commercial production in Argentina will scale-up rapidly in order to launch an export program of HB4 soybeans to China.

Argentinian Trade Show - Expoagro

In March of the last two years (2019 and 2020), Verdeca has showcased HB4 drought tolerant soybeans at **Expoagro**, Argentina's largest farm show, which is attended by over 150,000 attendees. During the exposition, Verdeca recruits South American growers to adopt HB4 soybean varieties for the upcoming growing season.



Arcadia Biosciences Presentation May 2019

ARCADIA'S GENE BUILDING PLATFORMS

TILLING is a form of reverse genetics that identifies single-base mutations in genes within a population of diverse plants. TILLING technology analyzes DNA samples with **high-throughput** laboratory equipment by detecting and screening allele (genes on a chromosome that determine hereditary characteristics). The process permits the **rapid and low-cost discovery** of novel alleles, along with the creation of DNA libraries of naturally diverse genetic plant populations. Of particular interest are the discoveries of gene alterations/mutations that produce beneficial traits, which can be developed into commercially-viable, differentiated agricultural products. TILLING has been used both as a discovery platform and as a crop breeding method. It is an alternative to transgenic (genetically modified) methods.



CRISPR is a gene-editing technology which uses a guide RNA molecule (that seeks out a gene of interest) and an endonuclease enzyme (that cleaves or cuts that targeted DNA sequence). Depending on the intended outcome, the targeted gene can be destroyed or be functionally modified.

CRISPR-Cas9 uses the Cas9 as the cutting endonuclease enzyme. A guide RNA searches for a DNA strand that is complementary to itself, which is the targeted DNA sequence to be edited. The Cas9 protein then cuts the DNA, at which point the genome can be modified, deleted or a new DNA sequence can be inserted. In 2017, Arcadia Biosciences in-licensed CRISPR-Cas9 gene-editing technology from the Broad Institute of MIT and Harvard. CRISPR-Cas9 complements Arcadia's TILLING platform, particularly since the combination of CRISPR-Cas9 and TILLING significantly reduce the time required to bring discoveries to market.

FINANCINGS

Initial Public Offering in 2015

Arcadia Biosciences completed its Initial Public Offering (IPO) on May 14, 2015. 8,200,000 common shares were offered at $8.00 per share, which provided **net proceeds of $61,008,000**. Credit Suisse, J.P. Morgan and Piper Jaffray were the underwriters of the offering. Since the IPO, a reverse 1-20 stock split occurred on January 23, 2018.

Financings in 2016 and 2017

No financing were necessary in 2016 and 2017.

Financings in 2018

During 2018, Arcadia closed a private placement of 1,201,634 shares of common stock and 1,282,832 warrants in May and a direct offering of 1,392,345 common stock at a purchase price of $9.93 and warrants in June for **net proceeds of approximately $21.3 million**. On May 11, 2018, Arcadia filed a shelf Registration Statement (Form S-3), which allows for the sale of $50 million worth of common stock, preferred stock, warrants and/o units from time to time up.

Financings in 2019

On June 12, 2019, Arcadia closed a registered direct offering (through a shelf registration) of 1,489,575 shares of common stock at $4.91 per share for gross proceeds of approximately $7.31 million. In a concurrent private placement, Arcadia issued 1,489,575 unregistered 5 ½-year warrants (exercisable into 1,489,575 common shares at a price of $5.00 per share) at a price of $0.125 per warrant for gross proceeds of approximately $186,000. **Net proceeds from issuance of common stock and warrants were approximately $6.88 million.** H.C. Wainwright & Co. was the exclusive placement agent for the offering. The net proceeds are intended for general corporate purposes and to pursue growth opportunities, which may include hemp germplasm acquisition, breeding and research activities and the scale-up of GoodWheat as well as for general and administrative expenses.

Around the first week in September 2019, the company **received approximately $5.269 million from the exercise of warrants** from prior financings.

On September 5, 2019**,** Arcadia Biosciences closed a registered direct offering (through a shelf registration) of 1,318,828 common shares $7.52 per share for gross proceeds of approximately $9.92 million. In a concurrent private placement, Arcadia issued 5 ½-year unregistered warrants (exercisable into 659,414 common shares at a price of $7.52 per share) at a price of $0.125 per warrant for gross

proceeds of approximately $82,000. **Net proceeds from issuance of common stock and warrants were approximately $9.22 million.** H.C. Wainwright & Co. was the exclusive placement agent for the offering.

2020

On May 18, 2020, several holders of warrants were permitted to purchase 1,392,345 shares of common stock at a reduced exercise price of $4.90 per share in return for the receipt of 1,392,345 new unregistered 5-year whole warrants exercisable at a price of $4.775 per share. Each whole warrant is exercisable for one share of common stock. **Net proceeds** are estimated to be **approximately $6.3 million**. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

VALUATION

For Arcadia Biosciences, a reasonable methodology is a discounted cash flow (DCF) model that estimates future cash flows and discounts them by using the cost of capital in order to attain a net present value. Arcadia's revenues for 2020 are being estimated using management's guidance while revenues in the out-years are being projected by industry forecasts and our estimates of the company's market share. The model is arranged by products lines, namely GoodHemp, GoodWheat, HB4 soybeans and SONOVA GLA.

Other assumptions relate to the cash costs, R&D expenses and the tax rate. To account for economies of scale, the company's gross margin increases as the top-line grows; therefore, cash costs as a percentage of sales are assumed to decline over time. R&D expenses are expected to increase at an 8% annual rate as the company continues to invest in new and ongoing genetic programs. The tax rate is anticipated to rise slowly until the current full corporate tax rate of 21% is attained.

The discount rate for large cap publicly-traded equities is usually in the 5%-to-10% range; however, for small cap companies, the discount rate is generally in the 12%-to-15% range due to a higher level of business risk. Since the outlook for Arcadia Biosciences is very positive with the company expected to generate meaningful sales over the next few quarters, we are using a discount rate of 12.5% in the DCF model.

The terminal value is calculated by multiplying the projected sales level in year six by the estimated terminal price-to-sales ratio (P/S) of 0.33, which is the average P/S ratio of a large agricultural products company.

It is well known that the results of DCF models are highly sensitive to the input assumptions. As the company reports subsequent quarters, the DCF model will be updated so that it accurately dovetails with reported financial results.

Our **DCF model values Arcadia Biosciences at $12.00 per share** on a fully diluted basis.

Arcadia BioSciences, Inc.

DCF Model

	2020	2021	2022	2023	2024	2025	2026
Revenues	9,840,000	20,750,990	40,926,096	80,088,841	145,504,553	199,664,229	273,571,463
Cash costs	23,714,400	39,634,391	57,705,795	72,880,845	129,499,052	173,707,879	232,535,743
R&D costs	9,672,000	10,445,760	11,281,421	12,183,934	13,158,649	14,211,341	15,348,248
Tax rate	0.0%	5.0%	10.0%	12.0%	15.0%	21.0%	21.0%
Free Cash Flow after R&D costs	-23,546,400	-27,862,703	-25,255,008	-4,378,826	2,419,824	9,278,557	20,293,102

Discount Rate	12.5%	
NPV	54,262,894	
Terminal Value	90,278,583	
Cash From Option Exercise	1,423,900	
Cash From Warrant Exercise	5,341,560	
Probability	95%	
Total Sum of Parts	143,741,589	
Debt	$0	1Q:2020
Cash	$16,018,000	1Q:2020
Current Shares	10,046,440	
Warrant/ Option Shares	3,246,656	1Q:2020
Diluted Shares	13,293,096	1Q:2020

Total NPV	159,759,589
Share Price	$12.02

Product line assumptions rely on an average of publicly-available market forecasts.

GoodHemp CBD products: The 2020 addressable market size is estimated to be approximately $1.4 billion, which is forecasted to increase rapidly to $24.6 billion by 2025, with growth primarily being driven by deregulation and an increasing level of demand for CBD health and wellness products. We model a 0.62% market penetration by 2021 with growth driven by the company's aggressive go-to-market plan that involves both increasing hemp production and broadening the company's distribution footprint.

GoodWheat: The initial addressable market size in 2020 is estimated to be approximately $8.0 billion, which is forecasted to increase at a CAGR of 11% to about $15 billion by 2026, with growth being driven by increasing demand for low-gluten, resistant starch products. We are modeling only a 0.004% market penetration in 2020, ramping up to 0.124% in 2026 as production increases and partnerships result in branded GoodWheat products being marketed under the company's brand strategy.

HB4 Soybeans: The estimated soybean market is huge with an estimated size of $150 billion in 2020. The addressable drought resistant soybean market is estimated to be around 16%-to-17% of the global market or approximately $25 billion. The addressable market is expected to increase at a 5% CAGR to about $33.5 billion in 2026. We model an initial 2021 market share of 0.004%, followed by a ramp up to 0.036% share in 2026, with the growth contingent on China permitting the importation GoodWheat from Argentina and Brazil.

SONOVA GLA Oils: The addressable market is estimated to be approximately $70 million in 2020 and forecasted to increase at a 2.5% CAGR to roughly $81 million by 2026. Market penetration in 2020 is expected to be about 1.6%. The product line is growing modestly, indicating a moderate rate of increasing market share. While SONOVA GLA is not a high growth segment, there is value in the product line and the underlying genetic technology.

Arcadia Biosciences, Inc.							
Markets ($000)	**2020**	**2021**	**2022**	**2023**	**2024**	**2025**	**2026**
GoodHemp	1,400,000	2,660,000	5,054,000	9,602,600	18,244,940	24,630,669	33,251,403
GoodWheat	8,000,000	8,880,000	9,856,800	10,941,048	12,144,563	13,480,465	14,963,316
HB4 Soybeans	25,000,000	26,250,000	27,562,500	28,940,625	30,387,656	31,907,039	33,502,391
SONOVA GLA	70,000	71,750	73,544	75,382	77,267	79,199	81,179
Market Penetration	**2020**	**2021**	**2022**	**2023**	**2024**	**2025**	**2026**
GoodHemp	0.600%	0.621%	0.642%	0.663%	0.684%	0.705%	0.726%
GoodWheat	0.004%	0.024%	0.044%	0.064%	0.084%	0.104%	0.124%
HB4 Soybeans	0.000%	0.004%	0.011%	0.028%	0.030%	0.033%	0.036%
SONOVA GLA	1.60%	1.65%	1.70%	1.75%	1.80%	1.85%	1.91%
Revenues ($000)	**2020**	**2021**	**2022**	**2023**	**2024**	**2025**	**2026**
GoodHemp	8,400	16,519	32,447	63,665	124,795	173,646	241,405
GoodWheat	320	2,131	4,337	7,002	10,201	14,020	18,555
HB4 Soybeans	0	919	2,894	8,103	9,116	10,529	12,061
SONOVA GLA	1,120	1,182	1,248	1,318	1,391	1,469	1,551
Total	**$9,840**	**$20,751**	**$40,926**	**$80,089**	**$145,505**	**$199,664**	**$273,571**

Steven Ralston, CFA. Zacks Small-Cap Research

RISKS

- Arcadia has funded operations primarily with the net proceeds from the initial public offering in 2015, private placements and stock offerings in 2018 and 2019, and operating revenues and grants (particularly in 2015 and 2016). Funds are still necessary to commercialize the company's efforts toward developing hemp, wheat and soy initiatives. Existing cash and short-term investments are not be sufficient to meet the company's anticipated cash requirements over the next year, which will require the company to access the capital markets for continues fund. Thus far, management has been able to effectively fund the company's operations and initiatives to date
- Shares outstanding increased dramatically in 2017 (+124%) and 2018 (+81%) as private placements and stock offerings funded the company's activities. Additional capital raises are expected despite the current impressive ramp up in hemp revenues. Considerable investments are still required to continue the R&D in hemp, wheat and soybeans.
- There are inherent risks related to the hemp industry. United States Federal and state laws (and regulations) are broad in scope and subject to interpretation. Any restrictions or requirements on hemp may negatively impact the company's operations and prospects. For example, currently, if Arcadia produced a "hot crop" (i.e. exceeds 0.3% THC), Arcadia must bear the costs of destroying the crop by a person authorized under the CSA to handle marijuana.
- As an agricultural biotechnology company, research and development expenses and operating costs may impede the company from attaining profitability.

BALANCE SHEET

Arcadia Biosciences, Inc. (In thousands)	Year 12/31/2016	Year 12/31/2017	Year 12/31/2018	Year 12/31/2019	1Q 2020 3/31/2020
ASSETS					
Cash and cash equivalents	2,013	9,125	11,998	8,417	12,973
Short-term investments	48,547	3,898	9,825	16,915	3,045
Accounts receivable	349	1,231	165	602	309
Unbilled revenue	184	4	3	0	0
Inventories, net	252	229	181	1,794	5,971
Prepaid expenses	877	560	704	712	1,460
Total current assets	**52,222**	**15,047**	**22,876**	**28,440**	**23,758**
Property and equipment, net	508	299	395	1,799	2,540
Right of use asset	-	-	-	1,963	5,654
Inventories, net — noncurrent	1,327	1,168	746	364	273
Long-term investments	2,498	0	0	0	0
Other noncurrent assets	19	56	7	8	23
TOTAL ASSETS	**56,574**	**16,570**	**24,024**	**32,574**	**32,248**
LIABILITIES AND STOCKHOLDERS' EQUITY					
Accounts payable and accrued expenses	2,359	2,496	2,645	4,685	4,912
Amounts due to related parties	30	29	29	40	16
Notes payable	-	-	-	24	31
Unearned revenue — current	740	1,000	96	42	17
Operating lease liability - current	-	-	-	611	526
Other current liabilities	0	0	284	306	306
Total current liabilities	**3,129**	**3,525**	**3,054**	**5,708**	**5,808**
Notes payable - noncurrent	25,127	-	-	107	130
Operating lease liability - noncurrent	-	-	-	1,497	5,312
Unearned revenue — noncurrent	3,120	2,038	-	-	-
Common stock warrant liabilities	-	-	5,083	14,936	6,775
Other noncurrent liabilities	3,000	3,000	3,072	2,000	2,000
Total Liabilities	**34,376**	**8,563**	**11,209**	**24,248**	**20,025**
Stockholders' Equity					
Common stock	44	42	45	49	49
Additional paid-in capital	173,723	175,223	191,136	214,826	215,612
Accumulated other comprehensive income	(19)	(1)	0	1	0
Accumulated deficit	(151,550)	(167,257)	(178,366)	(207,171)	(204,646)
Total Arcadia Biosciences stockholders' equity	**22,198**	**8,007**	**12,815**	**7,705**	**11,015**
Non-controlling interest			-	621	**1,208**
Total shareholder's equity	**22,198**	**8,007**	**12,815**	**8,326**	**12,223**
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY	**56,574**	**16,570**	**24,024**	**32,574**	**32,248**
Shares outstanding	2,224,384	2,134,154	4,774,919	8,646,149	8,654,095

Arcadia Biosciences, Inc.

Income Statement

(In '000, except share and share data) (For Years Ending December 31)	Year ending 12/31/2016	Year ending 12/31/2017	Year ending 12/31/2018	Year ending 12/31/2019	Year ending 12/31/2020 E
Revenues:					
Product	669	514	657	814	9,317
License	144	1,470	150	67	400
Royalty	0	0	0	0	30
Contract research & gov't grants	2,375	2,042	657	288	69
Total revenues	**3,188**	**4,026**	**1,464**	**1,169**	**9,815**
Cost of product revenues	895	283	661	885	7,580
Research and development	8,663	7,407	6,069	7,098	9,672
Selling, general & administrative	12,250	10,651	11,604	13,567	16,047
Chg in FV of contingent consideration	-	-	-	(1,000)	0
Total operating expenses	**21,808**	**18,341**	**18,334**	**20,550**	**33,299**
Gross profit (loss) from Operations	**(18,620)**	**(14,315)**	**(16,870)**	**(19,381)**	**(23,484)**
Interest (expense)	(1,319)	(747)	0	(5)	(12)
Stock warrant & adjustments (loss)	0	0	(4,000)	-	0
Chg in fair value of stock wt & adjust	0	0	9,561	(9,243)	8,161
Offering costs	0	0	(2,555)	(708)	(700)
Extinguishment of debt (loss)	0	(900)	0	0	0
Other income (expense)	340	281	394	466	280
Total other income (expense):	**(979)**	**(1,366)**	**3,400**	**(9,490)**	**7,729**
Income (loss) before income tax	(19,599)	(15,681)	(13,470)	(28,871)	(15,755)
Provision for income tax benefit (expense)	(25)	(26)	(10)	(2)	(68)
Attributable to non-controlling interest	-	-	-	68	102
Net Income (loss)	**(19,624)**	**(15,707)**	**(13,480)**	**(28,805)**	**(15,721)**
Net earnings per share (basic and diluted)	**($8.85)**	**($7.28)**	**($3.58)**	**($4.53)**	**($1.54)**
Net operating earnings per share (diluted)	**($8.85)**	**($7.28)**	**($6.12)**	**($3.07)**	**($2.33)**
Wgtd. avg. shares outstanding	2,218,341	2,156,201	3,766,419	6,363,112	10,237,785

Arcadia Biosciences, Inc.

Income Statement

(For Years Ending December 31)	Year ending 12/31/2019	Quarter ending 3/31/2020	Quarter ending 6/30/2020	Quarter ending 9/30/2020	Quarter ending 12/31/2020	Year ending 12/31/2020
Revenues:						
Product	814	154	1,398	3,114	4,651	9,317
License	67	100	100	100	100	400
Royalty	0	30	0	0	0	30
Contract research & gov't grants	288	25	20	19	4	69
Total revenues	**1,169**	**309**	**1,518**	**3,233**	**4,756**	**9,815**
Cost of product revenues	885	132	1,174	2,553	3,721	7,580
Research and development	7,098	2,244	2,356	2,474	2,598	9,672
Selling, general & administrative	13,567	3,723	3,909	4,105	4,310	16,047
Chg in FV of contingent consideration	(1,000)	0	0	0	0	0
Total operating expenses	**20,550**	**6,099**	**7,439**	**9,132**	**10,629**	**33,299**
Gross profit (loss) from Operations	**(19,381)**	**(5,790)**	**(5,922)**	**(5,899)**	**(5,873)**	**(23,484)**
Interest (expense)	(5)	(3)	(3)	(3)	(3)	(12)
Stock warrant & adjustments (loss)	0	0	0	0	0	0
Change in fair value of stock warrants	(9,243)	8,161	0	0	0	8,161
Offering costs	(708)	0	(350)	(350)	0	(700)
Other income (expense)	466	72	61	71	76	280
Total other income (expense):	**(9,490)**	**8,230**	**(292)**	**(282)**	**73**	**7,729**
Income (loss) before income tax	(28,871)	2,440	(6,214)	(6,181)	(5,800)	(15,755)
Provision for income tax benefit (expense)	(2)	(17)	(17)	(17)	(17)	(68)
Attributable to non-controlling interest	68	102				102
Net Income (loss)	**(28,805)**	**2,525**	**(6,231)**	**(6,198)**	**(5,817)**	**(15,721)**
Net earnings per share (basic and diluted)	**($4.53)**	**$0.29**	**($0.70)**	**($0.57)**	**($0.46)**	**($1.54)**
Net operating earnings per share (diluted)	**($3.07)**	**($0.65)**	**($0.70)**	**($0.57)**	**($0.46)**	**($2.33)**
Wgtd. avg. shares outstanding	6,363,112	8,651,213	8,929,485	10,817,285	12,553,156	10,237,785

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Steven Ralston, CFA, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover.

SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

---

[i] https://www.vivioninc.com/specials-promotions/
[ii] https://www.vivioninc.com/vivassure/
[iii] Projections: U.S. Leads in Global Hemp Cultivation https://www.hempgrower.com/article/projections-us-leads-global-hemp-cultivation/
[iv] Cannabidiol (CBD) Market by Product (Food Grade, Therapeutic Grade), Application (Neurogenerative Disorder, Fibromyalgia, Diabetes, Others), Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2019 to 2026 https://www.fiormarkets.com/report/cannabidiol-cbd-market-by-product-food-grade-therapeutic-396106.html
[v] Global Industrial Hemp Market Overview & Forecast, 2019 to 2025: Focus on Hemp Seed, Hemp Seed Oil, Hemp Fiber, and CBD Hemp Oil https://www.prnewswire.com/news-releases/global-industrial-hemp-market-overview--forecast-2019-to-2025-focus-on-hemp-seed-hemp-seed-oil-hemp-fiber-and-cbd-hemp-oil-300879995.html
[vi] Arcadia Biosciences Presentation April 2020, page 8
[vii] Food Fibers Market - Growth, Trends, and Forecast (2020 - 2025), Mordor Intelligence, https://www.mordorintelligence.com/industry-reports/food-fibers-market
[viii] Dietary Fibers Market worth $9.6 billion by 2025, https://www.marketsandmarkets.com/PressReleases/dietary-fibers.asp
[ix] Dietary Fibers Market by Type (Soluble and Insoluble), Application (Functional Food & Beverages, Pharmaceuticals, and Feed), Source (Fruits & Vegetables, Legumes, Cereals & Grains, and Nuts & Seeds), Processing Treatment, Region - Global Forecast to 2025, https://www.marketsandmarkets.com/Market-Reports/novel-dietary-fibers-market-858.html
[x] The New Food Fights: U.S. Public Divides Over Food Science, Pew Research Center, December 1, 2016, https://www.pewresearch.org/science/2016/12/01/the-new-food-fights/
[xi] U.S. organic sales break through $50 billion mark in 2018, https://ota.com/news/press-releases/20699
[xii] Kapoor R, Huang YS, Gamma linolenic acid: an anti-inflammatory omega-6 fatty acid. Curr Pharm Biotechnol. 2006 Dec; 7(6):531-4.
[xiii] John Newton, Ph.D., Chief Economist, Farm Bureau, China Uses One-Third of World's Soybeans, https://www.fb.org/market-intel/china-uses-one-third-of-worlds-soybeans